InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
85.07
(
-0.05%
)
Bitcoin
62,628.51
(
-0.07%
)
Post# of 12660
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

rancherho

Send PM Follow Ignore
Followers 8
Posts 190
Boards Moderated 0
Alias Born 10/30/2005

rancherho

Re: eagle-eye post# 1868

Thursday, 12/14/2006 3:05:51 PM

Thursday, December 14, 2006 3:05:51 PM

Post# of 12660
Glaxo's Tykerb appears to be a bigger competitive threat (and potential benefit for breast cancer patients) to both DNA's Herceptin and DNDN's Neuvenge. See:http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20061214:MTFH96037_2...

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up